

The paragraph at page 4, line 34 to page 5, line 3 has been amended as follows:

F2 -- As used herein, the term "flt3-ligand" refers to a genus of polypeptides that are described in United States Patent No. 5,554,512, EP 0627487 A2 and in WO 94/28391, both incorporated herein by reference. A human flt3-ligand cDNA was deposited with the American Type Culture Collection, **10801 University Boulevard, Manassas, VA 20110-2209, USA** (ATCC) on August 6, 1993 and assigned accession number ATCC 69382. The deposit was made under the terms of the Budapest Treaty. Flt3-L can be made according to the methods described in the documents cited above. --

In the Claims:

Please amend claims 6 and 20 as follows:

F3 6. (Three times amended) A method for augmenting an immune response in a patient having a cancerous or neoplastic disease, comprising the steps of administering flt3-ligand **to the patient** in an amount sufficient to generate an increase in the number of the patient's dendritic cells and administering a tumor antigen to the patient.

F4 20. (Three times amended) A method of treating cancerous or neoplastic disease in a patient in need thereof comprising administering flt3-ligand **to the patient** in an amount sufficient to enhance the patient's immune response to such disease and administering a tumor antigen to the patient.

Each of the Examiner's concerns will be addressed in the order presented in the Office Action.

1-3. Applicants acknowledge the change in Examiner and correspondence address, as well as establishment of a CPA filed on June 28, 2001. Claims 6, 7, 20 and 22-56 are pending in the application.